Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

16.08 +0.01 (+0.06%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,508
Open 16.03
Bid (Size) 16.00 (1)
Ask (Size) 16.14 (1)
Prev. Close 16.07
Today's Range 16.00 - 16.28
52wk Range 13.71 - 30.36
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire

Performance

YTD
+7.2%
+7.2%
1 Month
-4.3%
-4.3%
3 Month
-4.1%
-4.1%
6 Month
-0.1%
-0.1%
1 Year
+6.1%
+6.1%

More News

Read More
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.
From Telix Pharmaceuticals Limited
Via GlobeNewswire
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix to Host Investor Day in New York City on June 11, 2025
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Reports US$186M Q1 Revenue, Up 62% YOY
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Pharmaceuticals Touts Encouraging Data From Investigational Radiation Therapy In Relapsed Brain Cancer Patients
Via Benzinga
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
From Telix Pharmaceuticals Limited
Via GlobeNewswire
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Via Benzinga
Telix Announces Cardinal Health for Gozellix Commercial Distribution
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Five Below, Telix Pharmaceuticals, Dollar Tree And Other Big Stocks Moving Higher On Monday
Via Benzinga
Telix Appoints Paul Schaffer as Chief Technology Officer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Anne Whitaker Appointed as Non-Executive Director
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
From Telix Pharmaceuticals Limited
Via GlobeNewswire
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®
From Telix ARTMS, Inc.
Via GlobeNewswire
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Adds Lead-212 Isotope Production Capability
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum
From Telix Pharmaceuticals Limited
Via GlobeNewswire
FDA Accepts BLA for TLX250-CDx (Zircaix®) for Kidney Cancer Imaging, Grants Priority Review
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Recruitment Spotlight: Phase 3 Clinical Trial of Novel Prostate Cancer Radiopharmaceutical Now Active in Miami
From Telix Pharmaceuticals Limited
Via GlobeNewswire

Frequently Asked Questions

Is Telix Pharmaceuticals Limited - American Depositary Shares publicly traded?
Yes, Telix Pharmaceuticals Limited - American Depositary Shares is publicly traded.
What exchange does Telix Pharmaceuticals Limited - American Depositary Shares trade on?
Telix Pharmaceuticals Limited - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares?
The ticker symbol for Telix Pharmaceuticals Limited - American Depositary Shares is TLX on the Nasdaq Stock Market
What is the current price of Telix Pharmaceuticals Limited - American Depositary Shares?
The current price of Telix Pharmaceuticals Limited - American Depositary Shares is 16.08
When was Telix Pharmaceuticals Limited - American Depositary Shares last traded?
The last trade of Telix Pharmaceuticals Limited - American Depositary Shares was at 07/01/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.